07.08.2020 – 13:33
Press Release: Nidda Healthcare GmbH sets cash compensation for the transfer of the shares of the minority shareholders of STADA Arzneimittel AG at 98.51 EUR
Nidda Healthcare GmbH sets cash compensation for the transfer of the shares of the minority shareholders of STADA Arzneimittel AG at 98.51 EUR
Bad Vilbel, August 7, 2020 - Nidda Healthcare GmbH (Nidda), today reconfirmed to the management board of STADA Arzneimittel AG (STADA) its formal request from June 5 to transfer all shares of STADA's minority shareholders to Nidda and repeated the request providing further details. Nidda has asked that STADA convene an extraordinary general meeting at short notice to resolve on the transfer of the shares of STADA's minority shareholders to Nidda as the main shareholder in return for an adequate cash compensation. The cash compensation to be paid as consideration for the transfer of the shares has been determined by Nidda at 98.51 Euro per STADA share. The amount of the cash compensation will be reviewed by a court-appointed expert auditor to confirm the appropriateness of the cash compensation.
The Extraordinary General Meeting of STADA is expected to take place on September 24, 2020.
About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. As of December 31, 2019, STADA employed 11,100 people worldwide.
Additional information for journalists:
STADA Arzneimittel AG Media Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany Phone: +49 (0) 6101 603-165 Fax: +49 (0) 6101 603-215 E-Mail: email@example.com
Or visit us on the Internet at www.stada.com/press
Additional information for capital market participants:
STADA Arzneimittel AG Investor & Creditor Relations Stadastrasse 2-18 61118 Bad Vilbel - Germany' Phone: +49 (0) 6101 603-4689 Fax: +49 (0) 6101 603-215 E-mail: firstname.lastname@example.org
Or visit us on the Internet at www.stada.com/investor-relations